Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8785046 | Advances in Radiation Oncology | 2016 | 8 Pages |
Abstract
Chemopotentiating LDFRT combined with paclitaxel and carboplatin is effective in SCCHN and provided an excellent median overall survival of 107.2 months, with median PFS not yet reached in this locally advanced SCCHN cohort. This compares favorably to prior investigations and caused fewer grade 3 and 4 toxicities than more intensive, 3-drug induction regimens. This trial demonstrates the innovative use of LDFRT as a potentiator of chemotherapy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Susanne M. MD, Mahesh MD, Emily V. PhD, John F. MD, Natalie L. MD, William F. MD, Joseph MD,